Johnson & Johnson just delivered a 32.9% operating margin in Q3 2025 - the highest in company history - yet it trades at 19.4x earnings while peers like Eli Lilly and Merck command 23-24x multiples. Something doesn't add up.
The market is missing a powerful transformation story. After spinning off Consumer Health (Kenvue), JNJ has become a focused pharma/medtech innovator with accelerating growth, expanding margins, and a post-STELARA portfolio that's already thriving.
Key Investment Highlights
• Record margins: Q3 operating margin hit 32.9%, demonstrating the power of the post-Kenvue business mix
• Post-STELARA success: Pharma revenue ex-STELARA grew +16% despite losing a $10B drug - the diversification worked
• TREMFYA trajectory: Growing +40% YoY, capturing ~50% of new IL-23 IBD starts, $10B+ peak sales potential
• Margin expansion path: Sustained 29-30% operating margins by 2027 (vs 27% in 2024) = $0.50-0.60 EPS impact
• MedTech acceleration: Ortho separation unlocks 6.5%+ growth in remaining portfolio (Shockwave, Abiomed, EP)
• Valuation gap: 19.4x P/E vs 22-24x peers despite 30%+ ROE, 10%+ EPS CAGR, and fortress balance sheet
Our Recommendation: BUY
Price Target: $210 • Total Return: 12.8% • Risk/Reward: 2:1
Want to dig deeper into the numbers? The full report includes complete financial projections through 2027, detailed valuation analysis with sensitivity tables, peer comparisons, and 10 professional charts covering every angle of the investment case. Everything you need to make an informed decision.
